SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid mixed signals, with community frustration mounting over its stock performance despite positive developments. While initial discussion revolved around rumors of Nvidia abandoning Intel's 18A process, the recent clearance of Nvidia's $5 billion investment in Intel and the company's partnership in the US Department of Energy's "Genesis Mission" for AI are fueling optimism among long-term bulls regarding its advanced foundry initiatives and US government support.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending with high anticipation for an imminent FDA approval decision on its first-in-class drug, Narsoplimab, further amplified by a recent trading halt indicating news is pending. The community is buzzing with optimism for a positive outcome, expecting significant market movement and a potential short squeeze, especially given the company's strengthened financial standing from a major partnership deal.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a critical milestone signifying the company's transition toward commercial scalability for direct-to-device broadband. The community is buzzing with excitement, anticipating significant future growth and contract announcements, though some express caution regarding valuation and a potential "sell the news" reaction. This event firmly positions ASTS as a major player in the rapidly evolving space-based cellular network industry.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. (QBTS) is trending as the community anticipates upcoming showcases at CES 2026 and Qubits26, expected to highlight its commercial quantum computing applications and progress. While many express bullish sentiment on its long-term potential in a critical future industry, others debate its high volatility, current valuation relative to revenue, and executive share sales.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is a major talking point following its announced inclusion in the S&P MidCap 400. This news is generating significant community excitement, anticipating increased institutional demand, enhanced visibility, and a potential short squeeze. Investors are highlighting its strong financial position and its critical role in the rapidly evolving agentic AI and automation sector as key drivers for future growth.

Starfighters Space Inc

Starfighters Space Inc. (FJET), a recently public aerospace company, is trending due to extreme volatility driven by its low float and very high short interest. The community is fiercely divided, with many anticipating a significant short squeeze while others label it a pump-and-dump. There is widespread discussion about alleged market manipulation influencing its price action amidst this speculative fervor.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending following its acquisition by Sanofi, prompting widespread congratulatory messages among shareholders and discussions around the valuation of the deal. The acquisition, which enhances Sanofi's vaccine portfolio with Dynavax's Hepatitis B vaccine and shingles treatment, also fuels conversations regarding the implications for Vaxart due to their oral COVID-19 vaccine licensing agreement. This development provides a significant exit for long-term investors amid prior frustrations concerning management and shareholder value.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending following its strategic acquisitions, notably a pivot into the healthcare sector with biotech and wild ginseng resources, alongside earlier moves in EV charging and smart tech. This aggressive diversification is fueling a polarized debate, with proponents highlighting the low float and asset-backed growth potential, while skeptics caution about its history as a volatile Chinese microcap. The stock is also gaining attention amid a broader market rotation where capital is shifting from crowded mega-cap tech into under-the-radar small-cap plays.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending due to multiple strategic partnerships focused on deploying its advanced thin-film solar technology across aerospace, defense, and terrestrial applications. The community is actively discussing the stock's significant price and volume surges, viewing it as a high-potential speculative play driven by the burgeoning space economy and demand for resilient power in extreme environments.

Dolomite

Dolomite (DOLO) is generating significant buzz as its onchain matrix, emphasizing fully on-chain NAV and planned oracle feeds, is attracting trust signals from larger holders. The community is actively accumulating during recent pullbacks, with many expressing strong bullish sentiment and anticipating a substantial upward move, drawing comparisons to other tokens that have recently seen considerable gains. This widespread optimism positions DOLO as a potential key runner in the broader altcoin market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.</li><li>It said that the Wakix franchise delivered net revenue of approximately $239 million in the third quarter.&nbsp;</li></ul>Shares of Harmony Biosciences Holdings (HRMY) jumped 6% in the premarket session on Thursday after the company raised its full-year revenue guidance on strong Wakix sales.The firm now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251023496242/en/Harmony-Biosciences-Preannounces-Strong-Q3-2025-WAKIX-Performance-Raises-2025-Revenue-Guidance">expects</a> full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.<h2 class="st-heading-2">Excessive Sleepiness Medication Drives Revenue</h2>The company said that its Wakix franchise delivered net revenue of approximately $239 million in the third quarter (Q3), representing 29% year-over-year revenue growth. Wakix is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients six years of age and older with narcolepsy.Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, causing excessive daytime sleepiness and uncontrollable sleep attacks. Other symptoms include sudden loss of muscle control called cataplexy. The company said the increase in Wakix revenue was driven by higher average patient volume.The company is expected to report full Q3 earnings on November 4.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume remained at ‘low’ levels.Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">announced</a> that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance due to a higher-than-expected placebo response rate. Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability.CEO Jeffrey M. Dayno then highlighted the company’s strong portfolio, noting that it is on track to initiate late-stage trials of Wakix in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year.HRMY shares are down 24% this year and by about 23% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-nearly-64000-cybertrucks-over-concerns-with-front-parking-lights/cLG4hXGR3AH">Tesla Recalls Nearly 64,000 Cybertrucks Over Concerns With The Front Parking Lights</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?

The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.

Equity

Is Now the Time to Buy Small-Cap Stocks?

We discuss the outlook for small-cap stocks and highlight four ETFs.

The Zacks Analyst Blog Highlights MCOW, SCOW, SFLO and CALF

Pacer???s new MCOW and SCOW ETFs spotlight quality small- and mid-cap firms with strong free cash flow, joining rivals SFLO and CALF.

Looking for Quality ETFs in Smaller Caps? Tap 2 New FCF Aristocrats 

MCOW and SCOW debut with quality-focused strategies, targeting mid- and small-cap stocks with strong free cash flow records.



SFLO
Victory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SFLO News

SFLOVictory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF